Watch DMRA. Know when insiders buy.
One email the day a filing lands. Free.
DMRA
Damora Therapeutics, Inc.
26.84
+0.57 +2.17%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
58
WATCH · shorts 58
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.7BP/E 3.6DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$262.8MNET CASH —52W 2.75 – 34.14SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$35M | −$31.2M | — | -0.39 | −$21.9M | — | — | Aug 10 |
| Q1 2026 · Mar 31 | — | — | — | −$30.8M | −$27.8M | — | -0.62 | −$20.6M | — | — | May 12 |
| Q4 2025 · Dec 31derived | — | — | — | −$201.7M | −$200.7M | — | 10.86 | $566K | — | — | Mar 19 |
| Q3 2025 · Sep 30 | — | — | — | −$3.2M | −$3.1M | — | -2.36 | −$2.6M | — | — | Nov 6 |
| Q2 2025 · Jun 30 | — | — | — | −$3.4M | −$3.4M | — | -2.60 | −$2.2M | — | — | Aug 10 |
| Q1 2025 · Mar 31 | — | — | — | −$2.6M | −$2.5M | — | -1.92 | −$2.4M | — | — | May 12 |
| Q4 2024 · Dec 31derived | — | — | — | −$7.1M | −$6.7M | — | -5.23 | −$4.9M | — | — | Mar 19 |
| Q3 2024 · Sep 30 | — | — | — | −$3.8M | −$3.9M | — | -3.39 | −$3.7M | — | — | Nov 6 |
| Q2 2024 · Jun 30 | — | — | — | −$5.6M | −$5.3M | — | -4.92 | −$4.1M | — | — | Aug 5 |
| Q1 2024 · Mar 31 | — | — | — | −$5.7M | −$5.5M | — | -5.05 | −$5.9M | — | — | May 8 |
| Q4 2023 · Dec 31derived | — | — | — | −$6.7M | −$6.5M | — | -5.89 | −$11.5M | — | — | Mar 19 |
| Q3 2023 · Sep 30 | — | — | — | −$8.6M | −$8.1M | — | -7.50 | −$8.5M | — | — | Nov 1 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$210.9M | −$209.8M | — | 3.98 | −$6.7M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$22.3M | −$21.4M | — | -18.53 | −$18.6M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$39.9M | −$38.3M | — | -36.08 | −$36.9M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$61.2M | −$61.6M | — | -2.43 | −$42.9M | $196K | −$43.1M | — | — |
| FY2021 · to Dec 31 | — | — | −$52.2M | −$51.8M | — | -2.05 | −$52.3M | $223K | −$52.5M | — | — |
| FY2020 · to Dec 31 | — | — | −$33.6M | −$34.8M | — | -7.62 | −$38.2M | — | — | — | — |
Every number comes from Damora Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.